RosenstockJHansenLZeePLiYCookWHirshbergBet al
Resmetirom (Rezdiffra TM ), a liver-directed thyroid hormone receptor- (THR-) agonist, received accelerated FDA approval in March 2024 as the first agent specifically indicated for non-cirrhotic MASH with moderate-to-advanced fibrosis (F2-F3), based on the MAESTRO-NASH trial demonstrating MASH resolution and fibrosis improvement
Social media provides anonymity and emotional distancing, allowing judgment to become clickbait and Ozempic face photographs to go viral, leaving little room to consider why people were prescribed semaglutide in the first place
Many patients begin to notice a reduction in cravings and hunger within the first few weeks, which helps them to maintain a healthy eating plan
Together, these findings demonstrate that LS GLP-1R neurons can be effectively activated by liraglutide, possibly through the enhancement of excitatory synaptic transmission